Assessing the cost‐effectiveness of sodium–glucose cotransporter‐2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real‐world evidence

2020 ◽  
Vol 22 (12) ◽  
pp. 2364-2374
Author(s):  
Phil McEwan ◽  
Hayley Bennett ◽  
Kamlesh Khunti ◽  
John Wilding ◽  
Christopher Edmonds ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Type 2 Diabetes Mellitus ◽  
Economic Evaluation ◽  
Cost Effectiveness ◽  
Sodium Glucose Cotransporter ◽  
Real World Evidence ◽  
The Cost

scholarly journals Cost-effectiveness study of antidiabetic drugs in type 2 diabetes mellitus patients from Mumbai, India

2017 ◽  
Vol 4 (9) ◽  
pp. 3180 ◽  
Author(s):  
Dnyanesh Limaye ◽  
Krishna Todi ◽  
Jay Shroff ◽  
Ashutosh Ramaswamy ◽  
Priyanka Kulkarni ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Cross Sectional Study ◽  
Antidiabetic Drugs ◽  
Cross Sectional ◽  
Validated Questionnaire ◽  
The Cost

Background: Diabetes is fast gaining the status of a potential epidemic in India, with >62 million individuals currently diagnosed with the disease. India currently faces an uncertain future in relation to the potential burden that diabetes may impose on the country. An estimated US$ 2.2 billion would be needed to sufficiently treat all cases of type 2 diabetes mellitus (T2DM) in India. Many interventions can reduce the burden of this disease. However, health care resources are limited; thus, interventions for diabetes treatment should be prioritized. The present study assesses the cost-effectiveness of antidiabetic drugs in patients with T2DM from Mumbai, India.Methods: A prospective cross-sectional study was performed to assess the cost-effectiveness of antidiabetic drugs in patients with T2DM. Face-to-face interviews were conducted by using a validated questionnaire in a total of 152 (76 males, 76 females) patients with T2DM from F-North Ward, Mumbai, India. Cost-effectiveness was determined on the basis of cost of antidiabetic drug/s, efficacy, adverse drug reactions, safety of administration, frequency of administration, and bioavailability. Results: For treatment of T2DM in non-obese participants, Glimepiride+Pioglitazone costed least (`3.7) per unit of effectiveness followed by Glimepiride (`6.6), Gliclazide (`8.1), Repaglinide (`24.5), and Vildagliptin (`45.2). For treatment of T2DM in obese participants, Metformin cost least (` 6.7) per unit of effectiveness followed by Glimepiride + Metformin (`5.9) and Repaglinide (`24.5). Conclusions: In case of non-obese participants, cost effectiveness and prescribed treatments did not show a match, while for obese participants prescribed treatments were in line with cost effectiveness. 

scholarly journals The Cost-Effectiveness of Dulaglutide Versus Liraglutide in Patients with Type 2 Diabetes Mellitus in Taiwan

2016 ◽  
Vol 19 (7) ◽  
pp. A898
Author(s):  
H Lin ◽  
S Babineaux ◽  
T Lew ◽  
J Lowin ◽  
E Lovato ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
The Cost

The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan

2018 ◽  
Vol 21 (5) ◽  
pp. 488-496 ◽  
Author(s):  
Hitoshi Ishii ◽  
Matthew Madin-Warburton ◽  
Alena Strizek ◽  
Lucy Thornton-Jones ◽  
Shuichi Suzuki
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Insulin Glargine ◽  
The Cost

scholarly journals The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France

2017 ◽  
Vol 9 (1) ◽  
pp. 13-25 ◽  
Author(s):  
Mickael Basson ◽  
Dionysios Ntais ◽  
Ruba Ayyub ◽  
Donna Wright ◽  
Julia Lowin ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
Exenatide Qw ◽  
The Cost

scholarly journals PDB50 DOES THE APPLICATION OF UKPDS RISK EQUATIONS UNDERESTIMATE THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN TYPE 2 DIABETES MELLITUS?

2019 ◽  
Vol 22 ◽  
pp. S581
Author(s):  
P. McEwan ◽  
H. Bennett ◽  
B. Kartman ◽  
C. Edmonds ◽  
I. Gause-Nilsson ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cost Effectiveness ◽  
The Cost
Sign in / Sign up

Export Citation Format

Share Document